APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchPhosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market include Novartis AG, GlaxoSmithKline Plc, Bayer AG, AstraZeneca Plc, PIQUR Therapeutics AG, Karus Therapeutics Ltd and Curis Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Company

Novartis AG

GlaxoSmithKline Plc

Bayer AG

AstraZeneca Plc

PIQUR Therapeutics AG

Karus Therapeutics Ltd

Curis Inc

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Type

PQR-514

KA-2237

GSK-2636771

BAY-1082439

Others

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Application

Myelofibrosis

Renal Cell Carcinoma

Gastric Cancer

Metastatic Colorectal Cancer

Others

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform key companies, revenue, market share, and recent developments.

3. To split the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform significant trends, drivers, influence factors in global and regions.

6. To analyze Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform industry.

Chapter 3: Detailed analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Trends Table 2. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Drivers Table 3. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Opportunities and Challenges Table 4. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Restraints Table 5. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Company (2021-2026) Table 7. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Key Company Manufacturing Base & Headquarters Table 9. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company, Product Type & Application Table 10. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of PQR-514 Table 15. Significant Companies of KA-2237 Table 16. Significant Companies of GSK-2636771 Table 17. Significant Companies of BAY-1082439 Table 18. Significant Companies of Others Table 19. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type (2021-2026) Table 23. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Myelofibrosis Table 25. Significant Companies of Renal Cell Carcinoma Table 26. Significant Companies of Gastric Cancer Table 27. Significant Companies of Metastatic Colorectal Cancer Table 28. Significant Companies of Others Table 29. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application (2021-2026) Table 33. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application (2027-2032) Table 34. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Region (2021-2026) Table 37. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Region (2027-2032) Table 39. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Market Share by Country (2021-2026) Table 42. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Market Share by Country (2027-2032) Table 44. Novartis AG Company Information Table 45. Novartis AG Business Overview Table 46. Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 48. Novartis AG Recent Development Table 49. GlaxoSmithKline Plc Company Information Table 50. GlaxoSmithKline Plc Business Overview Table 51. GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 53. GlaxoSmithKline Plc Recent Development Table 54. Bayer AG Company Information Table 55. Bayer AG Business Overview Table 56. Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 58. Bayer AG Recent Development Table 59. AstraZeneca Plc Company Information Table 60. AstraZeneca Plc Business Overview Table 61. AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 63. AstraZeneca Plc Recent Development Table 64. PIQUR Therapeutics AG Company Information Table 65. PIQUR Therapeutics AG Business Overview Table 66. PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 68. PIQUR Therapeutics AG Recent Development Table 69. Karus Therapeutics Ltd Company Information Table 70. Karus Therapeutics Ltd Business Overview Table 71. Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 73. Karus Therapeutics Ltd Recent Development Table 74. Curis Inc Company Information Table 75. Curis Inc Business Overview Table 76. Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 78. Curis Inc Recent Development Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Image Figure 2. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size (2021-2032) & (US$ Million) Figure 4. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. PQR-514 Image Figure 8. KA-2237 Image Figure 9. GSK-2636771 Image Figure 10. BAY-1082439 Image Figure 11. Others Image Figure 12. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type (2021-2032) Figure 15. Myelofibrosis Image Figure 16. Renal Cell Carcinoma Image Figure 17. Gastric Cancer Image Figure 18. Metastatic Colorectal Cancer Image Figure 19. Others Image Figure 20. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application (2021-2032) Figure 23. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032) & (US$ Million) Figure 26. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032) & (US$ Million) Figure 32. South America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • PQR-514
  • KA-2237
  • GSK-2636771
  • BAY-1082439
  • Others
Applications
  • Myelofibrosis
  • Renal Cell Carcinoma
  • Gastric Cancer
  • Metastatic Colorectal Cancer
  • Others
Companies covered
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • AstraZeneca Plc
  • PIQUR Therapeutics AG
  • Karus Therapeutics Ltd
  • Curis Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Dynamics
  1. 2.1 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Trends
  2. 2.2 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Drivers
  3. 2.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Opportunities and Challenges
  4. 2.4 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Restraints
3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market by Company
  1. 3.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Revenue Ranking in 2025
  2. 3.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Company (2021-2026)
  3. 3.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Ranking (2024-2026)
  4. 3.4 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Manufacturing Base and Headquarters
  5. 3.5 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Product Type and Application
  6. 3.6 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market by Type
  1. 4.1 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Type Introduction
  2. 4.1.1 PQR-514
  3. 4.1.2 KA-2237
  4. 4.1.3 GSK-2636771
  5. 4.1.4 BAY-1082439
  6. 4.1.5 Others
  7. 4.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Type
  8. 4.2.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Type (2021-2032)
  10. 4.2.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type (2021-2032)
5 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market by Application
  1. 5.1 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Application Introduction
  2. 5.1.1 Myelofibrosis
  3. 5.1.2 Renal Cell Carcinoma
  4. 5.1.3 Gastric Cancer
  5. 5.1.4 Metastatic Colorectal Cancer
  6. 5.1.5 Others
  7. 5.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Application
  8. 5.2.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Application (2021-2032)
  10. 5.2.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application (2021-2032)
6 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Regional Value Analysis
  1. 6.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Region (2021-2032)
  3. 6.2.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Region: 2021-2026
  4. 6.2.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032)
  7. 6.3.2 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032)
  10. 6.4.2 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032)
  16. 6.6.2 South America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Country, 2025 VS 2032
7 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Country-level Value Analysis
  1. 7.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Country (2021-2032)
  3. 7.2.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Country (2021-2026)
  4. 7.2.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 Bayer AG
  14. 8.3.1 Bayer AG Company Information
  15. 8.3.2 Bayer AG Business Overview
  16. 8.3.3 Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  18. 8.3.5 Bayer AG Recent Developments
  19. 8.4 AstraZeneca Plc
  20. 8.4.1 AstraZeneca Plc Company Information
  21. 8.4.2 AstraZeneca Plc Business Overview
  22. 8.4.3 AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  24. 8.4.5 AstraZeneca Plc Recent Developments
  25. 8.5 PIQUR Therapeutics AG
  26. 8.5.1 PIQUR Therapeutics AG Company Information
  27. 8.5.2 PIQUR Therapeutics AG Business Overview
  28. 8.5.3 PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  29. 8.5.4 PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  30. 8.5.5 PIQUR Therapeutics AG Recent Developments
  31. 8.6 Karus Therapeutics Ltd
  32. 8.6.1 Karus Therapeutics Ltd Company Information
  33. 8.6.2 Karus Therapeutics Ltd Business Overview
  34. 8.6.3 Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  36. 8.6.5 Karus Therapeutics Ltd Recent Developments
  37. 8.7 Curis Inc
  38. 8.7.1 Curis Inc Company Information
  39. 8.7.2 Curis Inc Business Overview
  40. 8.7.3 Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  42. 8.7.5 Curis Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst